Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prediction of Tacrolimus-Posaconazole Interactions in Renal Transplant Patients with Different CYP3A5 Genotypes, Based on Physiological Pharmacokinetic Models.

Pharmaceutics·2026
Same author

Comparative efficacy and safety of colistin sulfate versus polymyxin B in critically ill patients with carbapenem-resistant gram-negative infections: a pilot inverse probability of treatment weighting-based retrospective cohort study.

BMC infectious diseases·2026
Same author

Model-informed vancomycin precision dosing by population pharmacokinetics combined with machine learning algorithms.

British journal of clinical pharmacology·2026
Same author

An Interpretable PK-Informed Hybrid Model for Voriconazole Exposure Prediction: Roles of CYP2C19 Genotype and Inflammation.

Drug design, development and therapy·2026
Same author

Rapid quantification of bile acids in serum by LC-MS/MS and application to serum bile acid profile in voriconazole administered patients with invasive fungal infections.

Bioanalysis·2026
Same author

Pharmacokinetics of CYP2C19- and CYP3A4-Metabolized Drugs in Cirrhosis Using a Whole-Body PBPK Approach.

Pharmaceutics·2025

Related Experiment Video

Updated: Jun 1, 2025

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

507

Tacrolimus and diabetic rodent models.

Minyan Qian1,2, Mengmeng Guan1,2, Liying Wang1

  • 1Department of Pharmacy, The First People's Hospital of Changzhou/The Third Affiliated Hospital of Soochow University, Changzhou, 213003, Jiangsu, China.

Pharmacological Reports : PR
|January 21, 2025
PubMed
Summary
This summary is machine-generated.

Tacrolimus (TAC), an immunosuppressant, can cause diabetes by impairing islet beta-cell function. This review summarizes TAC-induced diabetes models and potential therapeutic strategies to mitigate this adverse effect.

Keywords:
Animal modelDiabetes mellitusGlucose metabolism disorderMouseRatTacrolimus

More Related Videos

A Protocol for Constructing a Rat Wound Model of Type 1 Diabetes
05:18

A Protocol for Constructing a Rat Wound Model of Type 1 Diabetes

Published on: February 17, 2023

3.6K
Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

16.8K

Related Experiment Videos

Last Updated: Jun 1, 2025

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

507
A Protocol for Constructing a Rat Wound Model of Type 1 Diabetes
05:18

A Protocol for Constructing a Rat Wound Model of Type 1 Diabetes

Published on: February 17, 2023

3.6K
Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

16.8K

Area of Science:

  • Immunology
  • Endocrinology
  • Pharmacology

Background:

  • Tacrolimus (TAC) is a vital immunosuppressant in organ transplantation.
  • A significant adverse effect of TAC is glucose metabolism disorder, increasing diabetes risk.
  • Understanding TAC-induced diabetes mechanisms is crucial for prevention and treatment.

Purpose of the Study:

  • To systematically review rodent models of Tacrolimus-induced diabetes.
  • To summarize key molecular pathways involved in TAC-induced diabetes.
  • To assess interventions for managing TAC-induced glucose metabolism disorders.

Main Methods:

  • Systematic literature review of PubMed-indexed articles up to August 19, 2024.
  • Analysis of 48 studies on TAC-induced diabetic rodent models and 22 on TAC effects in diabetic/obese models.
  • Summarization based on TAC dosage, administration, duration, and glucose metabolism indices.

Main Results:

  • TAC impairs islet beta-cell function via CaN/NFAT, PI3K/AKT/mTOR, and TGF-β/Smad pathways.
  • TAC induces non-obese diabetic models mimicking type 2 diabetes and post-transplantation diabetes mellitus.
  • Dose reduction, discontinuation, and various pharmacological agents can modulate TAC-induced diabetes.

Conclusions:

  • TAC-induced diabetes is a significant concern in transplantation.
  • Rodent models provide valuable insights into diabetes pathogenesis and treatment.
  • This review guides the selection of appropriate animal models for future research.